Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentostatin and Low-Dose TBI Conditioning for AlloPSCT
NCT00571662Phase 2Completed
- Sponsor
- University of Nebraska
- Start
- Dec 2000
- Primary completion
- Dec 2008
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pentostatin in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML) and 6 more, sponsored by University of Nebraska. Primary endpoints: Percent of Participants With Full Donor Chimerism and Toxicity for the Combination of Pentostatin and Low Dose Total Body Irradiation. Started Dec 2000; status: completed.
02
Drugs
pentostatin
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)chronic lymphocytic leukemia (CLL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00571662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00571662.